Nurix Therapeutics, Inc.
Nurix Therapeutics (NRIX) will report Q3'26 earnings on October 09. Analysts estimate revenue of 24.35M USD and EPS of (0.60) USD. Details are available on the company's Financials page.
Nurix Therapeutics (NRIX) shares rose 50% premarket after a $2.3B deal with Roche (RHHBY) to develop blood cancer therapy bexobrutideg. Roche will pay $700M upfront, with potential milestone payments. The drug targets a $41B market, including chronic lymphocytic leukemia.
Nurix said Sanofi began a Phase 1 first-in-human trial of SAR448272/NX-3911, an oral STAT6 degrader, triggering a $10 million milestone payment. Nurix reported it has received about $139 million from its 2019 Sanofi collaboration and remains eligible for about $453 million in further STAT6-related milestones. Sanofi runs the trial, with U.S. co-development and co-promotion options for Nurix.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning NRIX (Nurix Therapeutics, Inc.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent NRIX coverage spans mergers & acquisitions, earnings and technology.
In the last 30 days, NRIX insiders filed 2 SEC Form 4 transactions — no purchases and 2 sales ($149K). The most active reporter was Ring Christine, Chief Legal Officer, with 2 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
Ahead of the Oct. 9 earnings release, the article provides consensus-style Q3'26 revenue and EPS expectations that can anchor positioning and volatility.
Deal adds significant upfront cash and future milestones, likely supporting near‑term upside.
Phase 1 start and milestone cash flow increase near-term visibility on the STAT6 degrader program and potential US co-promotion decision timing.
Street PT hike reinforces bullish expectations for Nurix’s pipeline and partnership-driven growth, but it is still an analyst action rather than a new company disclosure.
The Roche deal materially de-risks funding and expands commercial and clinical optionality for bexobrutideg, supporting a higher valuation multiple versus standalone peers.
AlphAI scores every news story that mentions NRIX with an AI model for sentiment and relevance, and aggregates insider trades from Nurix Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Nurix Therapeutics (NRIX) will report Q3'26 earnings on October 09. Analysts estimate revenue of 24.35M USD and EPS of (0.60) USD. Details are available on the company's Financials page.
1 min readNurix Therapeutics (NRIX) shares rose 50% premarket after a $2.3B deal with Roche (RHHBY) to develop blood cancer therapy bexobrutideg. Roche will pay $700M upfront, with potential milestone payments. The drug targets a $41B market, including chronic lymphocytic leukemia.
2 min readNurix said Sanofi began a Phase 1 first-in-human trial of SAR448272/NX-3911, an oral STAT6 degrader, triggering a $10 million milestone payment. Nurix reported it has received about $139 million from its 2019 Sanofi collaboration and remains eligible for about $453 million in further STAT6-related milestones. Sanofi runs the trial, with U.S. co-development and co-promotion options for Nurix.
3 min readMorgan Stanley raised its Nurix Therapeutics (NRIX) price target to $38 from $36 and kept an Overweight rating. NRIX trades around $23.43, implying about 43% upside to the consensus target. The article also notes multiple other analyst target increases tied to Nurix’s Roche collaboration and clinical updates.
4 min readNurix Therapeutics (Nasdaq: NRIX) reported fiscal Q2 2026 results and a corporate update. It entered a global Roche collaboration for bexobrutideg (NX-5948) with up to $2.3B total payments, including a $700M upfront. Nurix said EHA data showed CLL/SLL ORR of 83% (PFS 22.1 months) and cash of $443.5M as of May 31, 2026.
6 min readNurix Therapeutics, Inc. (NRIX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 nrix-20260709xexx991.htm EX-99.1 Document Exhibit 99.1 [Nurix logo] Nurix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update Entered into global collaboration with Roche for bexobrutideg, with potential total payments of up to $2.3
6 min readNurix Therapeutics (NRIX) extended gains for an eighth straight session, reaching a 52-week high of $23.09 and closing up 16.37% at $22.46, according to trading data cited in the article. The move followed Nurix’s partnership with Roche to co-develop and commercialize bexobrutideg, with $700 million upfront and up to $2.3 billion in milestones, the companies said.
4 min readRing Christine (Chief Legal Officer) sold 28,935 shares of Nurix Therapeutics, Inc. (NRIX) at $20.06 ($0.58M total) on 2026-06-25 under a Rule 10b5-1 trading plan.
2 min readDelveInsight reports the chronic spontaneous urticaria (CSU) market in the 7MM was about $2 billion in 2025, with roughly 4.8 million diagnosed prevalent cases, expected to rise by 2036. The US led in 2025. The report cites emerging therapies including Celldex’s barzolvolimab, Sanofi’s rilzabrutinib, and Jasper’s briquilimab, plus FDA approval of dupilumab for pediatric CSU.
6 min readMarkets settled higher as inflation expectations eased; the 10-year breakeven rate fell to 2.452%. European yields rose, with Germany’s 10-year Bund at 3.060% (+2.2 bp) and UK gilt at 4.943% (+4.0 bp). Eurozone Sentix confidence improved to -3.4. Chipmakers rallied: Intel +11% after Google ordered 3 million Tensor Processing Units for 2028; others also gained.
7 min read
